Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Sells $247,796.10 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Carole Ho sold 12,255 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the transaction, the insider now directly owns 178,580 shares in the company, valued at $3,610,887.60. This represents a 6.42 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Denali Therapeutics Stock Performance

Denali Therapeutics stock traded up $0.07 during midday trading on Wednesday, hitting $21.25. 1,245,656 shares of the company’s stock were exchanged, compared to its average volume of 1,173,671. The company has a market cap of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39. The stock has a 50-day moving average price of $24.34 and a two-hundred day moving average price of $24.88. Denali Therapeutics Inc. has a 52-week low of $14.56 and a 52-week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the prior year, the firm earned ($0.72) earnings per share. As a group, sell-side analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on DNLI shares. HC Wainwright lowered their price objective on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday. Robert W. Baird initiated coverage on shares of Denali Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $31.00 price target on the stock. William Blair began coverage on shares of Denali Therapeutics in a research note on Friday, January 3rd. They issued an “outperform” rating for the company. Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.91.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. MONECO Advisors LLC lifted its holdings in shares of Denali Therapeutics by 4.6% during the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock worth $265,000 after acquiring an additional 400 shares during the last quarter. Assetmark Inc. raised its position in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after purchasing an additional 580 shares in the last quarter. CWM LLC raised its position in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after purchasing an additional 654 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares in the last quarter. Finally, Quest Partners LLC bought a new position in shares of Denali Therapeutics during the 3rd quarter valued at about $73,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.